TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00589693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 4-hour infusion of doripenem will be administered every 8 hours for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem-Cilastatin
Description: Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 1-hour infusion of imipenem-cilastatin will be administered every 8 hours for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.
Study: NCT02559531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile triage system
Description: A mobile triage system used by EMS providers will be evaluated using standardized clinical vignettes
Study: NCT03971669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivotif Typhoid Oral Vaccine
Description: The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
Study: NCT01248611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: nasally, dose titrated to effect
Study: NCT04537078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chorionic Gonadotropin
Description: will be used in the second cycle of the second arm for ovulation triggering in a dose of 10,000 IU when the leading follicle \>18 mm in diameter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Oral Contraceptive
Description: luteal phase priming from day 21 of the cycle before controlled ovarian stimulation for one week .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Oral Contraceptive
Description: luteal phase priming from day 21 of the cycle before controlled ovarian stimulation for one week .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclo-Progynova
Description: Starting from cycle Day 3 of the intented cycle for thawed embryo transfer, patients will receive the white tablets of Cyclo-Progynova daily. From Day 10 onwards, endometrium growth will be monitored by transvaginal ultrasound.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclo-Progynova
Description: Starting from cycle Day 3 of the intented cycle for thawed embryo transfer, patients will receive the white tablets of Cyclo-Progynova daily. From Day 10 onwards, endometrium growth will be monitored by transvaginal ultrasound.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone
Description: in the intended cycle of embryo transfer when endometrial thickness ≥ 7 mm. Progesterone administration (as 800 mg/day vaginal suppositories per day and 100 mg ampule IM every other day) will be continued until pregnancy testing 18 days after embryo transfer and in pregnant cases will continued till the 12 weeks of gestation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone
Description: in the intended cycle of embryo transfer when endometrial thickness ≥ 7 mm. Progesterone administration (as 800 mg/day vaginal suppositories per day and 100 mg ampule IM every other day) will be continued until pregnancy testing 18 days after embryo transfer and in pregnant cases will continued till the 12 weeks of gestation.
Study: NCT04346797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Intravenous administration as follows:~Induction dosage regimen at 1200 mg on Days 1, 4, 8 then 1200 mg or 900 mg on Day 12 depending on the monitoring of Eculizumab Plasma Level and CH5O and sC5B9 and maintenance doses of 900 mg on Days 15, 18 and 22
Study: NCT04087759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (Test formulation)
Description: Participants will receive bedaquiline orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (Test formulation)
Description: Participants will receive bedaquiline orally.
Study: NCT00179374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored telephone intervention of education
Description: Tailored telephone intervention to promote metabolic control of diabetes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Print educational intervention
Description: diabetes educational materials by mail
Study: NCT04234152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photo-protection
Description: The MV solution is delivered from producing companies in amber vials. The MV will be sampled by the pharmacy technician in a syringe that is photo-protected with a white label indicating the subject study name, protocol number and the infusion rate. The MV will be transported to the unit in the same photo-protected syringe. In the neonatal unit, this syringe will be installed in the pump and connected to photo-protected extension duration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: This group will receive the standard practice of PN compounding in the pharmacy followed by infusion in standard infusion kit available in Sainte-Justine's Hospital.
Study: NCT02072174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaferon for Children
Description: Anaferon for children: For oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anaferon for Children
Description: Anaferon for children: For oral use.
Study: NCT04087759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (Test formulation)
Description: Participants will receive bedaquiline orally.
Study: NCT03130582

Intervention type: DRUG
Intervention: high-dose etoposide
Description: an epipodophyllotoxin, is one of the most common chemotherapy agents for lymphoma without reciprocal resistance with other kinds of agents.

Intervention type: DRUG
Intervention: high-dose etoposide
Description: an epipodophyllotoxin, is one of the most common chemotherapy agents for lymphoma without reciprocal resistance with other kinds of agents.
Study: NCT05960539

Intervention type: PROCEDURE
Intervention: surgical training
Description: surgical residency focussed on visceral robotic procedures
Study: NCT02537912

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sugarlock®
Description: Subjects ingested 2 capsules (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects ingested 2 capsules placebo in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
Study: NCT02948179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preimplantation Genetic Diagnosis
Description: Using Preimplantation genetic diagnosis, including multiple annealing and looping-based amplification cycles amplification technique, the investigators have had screened out healthy embryos by In Vitro Fertilization. Then the investigators transplanted embryos returned to the parent. Finally, participants will have healthy baby without pathogenic gene inheritance.
Study: NCT04182022

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency management: Contingent incentives
Description: Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions and verified abstinence from alcohol.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Contingency management: Noncontingent incentives
Description: Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions only with no contingency on alcohol use.
Study: NCT03611751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days
Study: NCT01250860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Derotational manual therapy techniques in selected segments in spine
Description: Derotational manual therapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham therapy
Study: NCT02596451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium gel, 1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltaren® Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02133846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287 2 mg/m2
Description: 2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.Drug: Placebo Drug: Placebo 500mL 0.9% sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI-287 20 mg/m2
Description: 20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500mL 0.9% sodium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 500mL 0.9% sodium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 500mL 0.9% sodium chloride
Study: NCT03611751

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT02133846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 500mL 0.9% sodium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI-287 6.3 mg/m2
Description: 6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
Study: NCT03611751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: Specified dose on specified days
Study: NCT00838344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Adherence Program (MAP)
Description: Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
Study: NCT02559908

Intervention type: DEVICE
Group type: OTHER
Intervention: Hyaluronic Acid Injectable Gel
Description: Hyaluronic Acid Injectable Gel (VYC-25L) injection into the chin and/or jaw areas (up to 4.0 mLs).
Study: NCT03443219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spritztube®
Description: After preoxygenation, anaesthesia was induced with midazolam, propofol, and fentanyl,Spritztube® was inserted and both cuffs inflated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme™
Description: After preoxygenation, anaesthesia was induced with midazolam, propofol, and fentanyl,LMA Supreme™ was inserted and both cuffs inflated
Study: NCT04087759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (Test formulation)
Description: Participants will receive bedaquiline orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (Test formulation)
Description: Participants will receive bedaquiline orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (Test formulation)
Description: Participants will receive bedaquiline orally.
Study: NCT03980860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Type
Description: The implementation of 2 types of exercise programs to reduce body fat

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Type
Description: The implementation of 2 types of exercise programs to reduce body fat
Study: NCT01392170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFNá-2a
Description: 45 mcg given subcutaneously as a single weekly dose for 24 months.
Study: NCT02052037

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg inclusion
Description: Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week)in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions. Treatment phase will last for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg exclusion
Description: Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products.~During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained. Treatment phase will last for 12 weeks.
Study: NCT00769158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate and Naltrexone
Description: Topiramate 200 mg and Naltrexone 50 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT04064528

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acids
Description: 10 g bolus of essential amino acids

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acids
Description: 10 g bolus of essential amino acids
Study: NCT04313686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy
Description: Based on randomization, those who first receive the mindfulness training program are the intervention group. Participants would meet weekly for 2-3-hour long sessions for six weeks at the patient's usual follow-up clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No-intervention
Description: Participants who were randomized into this group would continue to receive their usual follow-up care at the usual neurology outpatient clinic.
Study: NCT00677586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simultaneous resection of liver metastasis and the rectal primary tumor
Description: simultaneous resection of liver metastasis and the rectal primary tumor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: staged resection of liver metastasis and the rectal primary tumor
Description: Patients received resection of the rectal tumor. 1 months later received resection of liver metastasis
Study: NCT03056001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion on day 1 of each 3 week cycle, at dose of 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV injection on day 1 of each 3 week cycle, starting at dose of 60 mg/m2 (may be escalated to 75 mg/m2 per investigator discretion after Cycle 1)
Study: NCT02832739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENACA - ICT based self-management support system
Description: SENACA - ICT based self-management support system is a structured self-management support system with several interacting components, combining tele-monitoring devices and a solution for personalised health plans. ==\> www.senaca.ch
Study: NCT00657917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin +Gentamicin topical cream
Description: WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.
Study: NCT01393717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Given IV
Study: NCT00922337

Intervention type: DEVICE
Intervention: MGuard Coronary Stent system
Description: MGuard Coronary Stent system implanted within a PCI
Study: NCT02212561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given orally on days 1,3,8,10,22 and 24 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate/hydrocortisone/cytarabine
Description: Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
Study: NCT04307537

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post-urethroplasty urethrography
Description: Imaging of the urethra after reconstructive surgery to identify contrast leakage (no, insignificant, signficant).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-urethroplasty urethrography
Description: Imaging of the urethra after reconstructive surgery to identify contrast leakage (no, insignificant, signficant).
Study: NCT02059369

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI+CFAE+DCC
Description: pulmonary vein Isolation (PVI), CFAE for substrate modification and direct current cardioversion (DCC) if AF persists

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI, CFAE, anterior and roof line, DCC
Description: PVI, CFAE ablation. If AF persists linear lesions (anterior and roof line), cardioversion if AF persists
Study: NCT00839007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-NP
Description: Infusion of CD-NP at one of up to 6 doses or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-NP
Description: Infusion of CD-NP at one of up to 6 doses or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-NP
Description: Infusion of CD-NP at one of up to 6 doses or placebo
Study: NCT02559908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid Injectable Gel
Description: Hyaluronic Acid Injectable Gel (VYC-25L) injection into the chin and/or jaw areas (up to 4.0 mLs).
Study: NCT05009849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Exercises
Description: The exercises in the Exercise I arm (Yoga and conventional exercises) will be upgraded to Phase II. Patients will be allowed to attend a minimum of four out of seven days in Phase I and II. Patients will be assessed at 6-9 months for compliance to phase II exercises. Only if patients are fulfilling the criteria for accuracy, sequence and duration of phase II exercises, will they be taught phase III exercises. Patients who are unable to do phase II exercises accurately or demonstrate non compliance to the exercise routine at first follow up visit/ 6-9 months will be re taught phase II exercises. These patients will be upgraded to phase III only if able to perform phase II adequately at assessment. Six months after completion of phase III exercises, patients will be assessed for compliance to phase III exercises. These women's will be assessed at the subsequent 6-9 month follow up and compliance will be evaluated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Exercises
Description: The exercises in the Exercise I arm (Yoga and conventional exercises) will be upgraded to Phase II. Patients will be allowed to attend a minimum of four out of seven days in Phase I and II. Patients will be assessed at 6-9 months for compliance to phase II exercises. Only if patients are fulfilling the criteria for accuracy, sequence and duration of phase II exercises, will they be taught phase III exercises. Patients who are unable to do phase II exercises accurately or demonstrate non compliance to the exercise routine at first follow up visit/ 6-9 months will be re taught phase II exercises. These patients will be upgraded to phase III only if able to perform phase II adequately at assessment. Six months after completion of phase III exercises, patients will be assessed for compliance to phase III exercises. These women's will be assessed at the subsequent 6-9 month follow up and compliance will be evaluated.
Study: NCT00839007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-NP
Description: Infusion of CD-NP at one of up to 6 doses or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-NP
Description: Infusion of CD-NP at one of up to 6 doses or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-NP
Description: Infusion of CD-NP at one of up to 6 doses or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD-NP
Description: Infusion of CD-NP at one of up to 6 doses or placebo